MK-677 vs Ipamorelin: GH secretagogue comparison for bodybuilders

MK-677 (ibutamoren) and ipamorelin are both growth hormone secretagogues used by bodybuilders to elevate IGF-1, but they work through different mechanisms and carry very different risk profiles.

MK-677 is an oral ghrelin mimetic with a 24-hour half-life. It produces continuous, sustained GH elevation throughout the day, driving higher absolute IGF-1 levels but with significant insulin resistance, appetite stimulation, and water retention. Its convenience (once-daily oral dosing) makes it the most popular GH secretagogue in the bodybuilding community.

Ipamorelin is an injectable GHRP with a 2-hour half-life. It produces discrete GH pulses that mimic the body's natural pulsatile secretion pattern. This results in lower absolute IGF-1 elevation but with minimal metabolic side effects: no cortisol release, no prolactin elevation, no appetite stimulation, and far less insulin resistance than MK-677.

The choice between them comes down to priorities: maximum IGF-1 elevation and convenience (MK-677) vs. metabolic safety and hormonal selectivity (ipamorelin).

GH release pattern: MK-677 produces sustained, continuous GH elevation over 24 hours. Ipamorelin produces discrete pulses lasting 2-3 hours. This is the single most important pharmacological distinction. Sustained GH drives more insulin resistance because tissues never get recovery windows between GH exposure.

Route and convenience: MK-677 is oral (one pill daily). Ipamorelin requires subcutaneous injection 1-3 times daily. For many users, this convenience factor alone determines their choice.

IGF-1 ceiling: MK-677 at 25 mg/day typically raises IGF-1 by 50-100% (equivalent to 2-3 IU of exogenous GH). Ipamorelin at standard doses raises IGF-1 by 15-40%, or up to 60% when combined with CJC-1295.

Insulin resistance: MK-677 has documented insulin resistance in a 2-year RCT (Nass et al., 2008): fasting glucose rose 0.3 mmol/L and HbA1c rose 0.2%. Ipamorelin's insulin resistance risk is minimal due to its pulsatile GH pattern.

Appetite: MK-677 significantly increases appetite through ghrelin receptor activation. This can be beneficial during bulking but problematic during cutting or for metabolically sensitive users. Ipamorelin has no appetite-stimulating effect.

Hormonal selectivity: Ipamorelin does not release ACTH, cortisol, prolactin, or gonadotropins even at doses 200x the effective GH dose (Raun et al., 1998). MK-677 mildly elevates prolactin and has direct ghrelin-receptor effects on pancreatic function and central appetite regulation.

Water retention: MK-677 causes noticeable water retention and bloating in many users. Ipamorelin causes minimal water retention.

Evidence base: MK-677 has 2-year RCT data (Nass et al., 2008) and multiple shorter trials. Ipamorelin has Phase I pharmacokinetic/pharmacodynamic data (Raun et al., 1998; Gobburu et al., 1999) but no long-term efficacy RCT.

Choose MK-677 if:

• Convenience is a priority (oral dosing, no injections)
• You want maximum IGF-1 elevation from a secretagogue
• You are in a bulking phase and the appetite increase is beneficial
• You have good baseline metabolic health (fasting glucose below 90, HbA1c below 5.4%)
• You are willing to monitor glucose, insulin, and HbA1c every 3 months

Choose ipamorelin if:

• You have any insulin resistance risk factors (family history of diabetes, high body fat, borderline glucose)
• You are in a cutting phase where appetite stimulation would be counterproductive
• You want GH benefits without metabolic side effects
• You are stacking with compounds that already stress metabolic health (e.g., GLP-1 agonists, AAS)
• You are comfortable with subcutaneous injections
• You want the cleanest hormonal profile (no cortisol, prolactin, or appetite effects)

Choose ipamorelin + CJC-1295 (no DAC) if:

• You want to close the IGF-1 gap with MK-677 while maintaining the pulsatile GH pattern
• This combination amplifies GH pulses for higher IGF-1 than ipamorelin alone, with minimal metabolic cost